Schistosoma: Difference between revisions
From IDWiki
Schistosoma
(ββ) |
(ββ) |
||
| Line 25: | Line 25: | ||
== Management == |
== Management == |
||
* Acute |
* Acute |
||
** Praziquantel 40mg/kg |
** [[Is treated by::Praziquantel]] 40mg/kg given over one day split into 3 doses |
||
*** Can cause nausea, dizziness, and fever |
|||
* Chronic |
* Chronic |
||
** [[Is treated by::Praziquantel]] 20-40 mg/kg or 40-60 mg/kg (if at risk for ''S. japonica'') |
|||
** Prevention |
|||
** Given over one day split into 3 doses, then repeated 6 weeks later |
|||
== Prognosis == |
== Prognosis == |
||
Revision as of 18:44, 10 December 2019
- Infection with a species of the genus Schistosoma
Species
- Schistosoma mansoni: liver and gut
- Schistosoma haematobium: GU/pelvis
- Schistosoma japonicum: liver and gut
- Schistosoma mekongi: Mekong basin
Risk Factors
- Fresh water exposure in endemic countries
Clinical Presentation
Investigations
- Labs
- CBC, showing eosinophilia
- Schisto serology (only positive 6 weeks after infection)
- Egg detection in stool, urine, semen, or tissue biopsy
- Imaging
- Eggs can cause granulomatous disease in various organs
- Bladder polyps and obstruction may be seen on ultrasound
Management
- Acute
- Praziquantel 40mg/kg given over one day split into 3 doses
- Chronic
- Praziquantel 20-40 mg/kg or 40-60 mg/kg (if at risk for S. japonica)
- Given over one day split into 3 doses, then repeated 6 weeks later
Prognosis
- Increased risk of squamous cell carcinoma, which increase with young age at infection, duration of infection, high burden of infection, and bladder wall fibrosis
References
- ^ Archana Asundi, Alina Beliavsky, Xing Jian Liu, Arash Akaberi, Guido Schwarzer, Zeno Bisoffi, Ana Requena-MΓ©ndez, Ian Shrier, Christina Greenaway. Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis. The Lancet Global Health. 2019;7(2):e236-e248. doi:10.1016/s2214-109x(18)30490-x.
